These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 7994248)
1. 15-Deoxyspergualin controls cyclosporin- and steroid-resistant intestinal acute graft-versus-host disease after allogeneic bone marrow transplantation. Kasai M; Higa T; Naohara T; Masauzi N; Watanabe M; Matsuura A; Ohizumi H; Tanaka J; Morii K; Kiyama Y Bone Marrow Transplant; 1994 Aug; 14(2):315-7. PubMed ID: 7994248 [TBL] [Abstract][Full Text] [Related]
2. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087 [TBL] [Abstract][Full Text] [Related]
3. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bertz H; Afting M; Kreisel W; Duffner U; Greinwald R; Finke J Bone Marrow Transplant; 1999 Dec; 24(11):1185-9. PubMed ID: 10642806 [TBL] [Abstract][Full Text] [Related]
4. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Cahn JY; Bordigoni P; Tiberghien P; Milpied N; Brion A; Widjenes J; Lioure B; Michel G; Burdach S; Kolb HJ Transplantation; 1995 Nov; 60(9):939-42. PubMed ID: 7491697 [TBL] [Abstract][Full Text] [Related]
5. Differences between lymphocyte subsets, after allogeneic bone marrow transplantation, in patients who received tacrolimus and patients who received cyclosporin A. Fukuda H; Teshima H; Karasuno T; Hiraoka A; Nakamura H; Masaoka T Int J Hematol; 2000 Jan; 71(1):70-4. PubMed ID: 10729997 [TBL] [Abstract][Full Text] [Related]
6. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase. Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473 [TBL] [Abstract][Full Text] [Related]
7. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799 [TBL] [Abstract][Full Text] [Related]
8. Orthoclone OKT3 for graft failure after allogeneic bone marrow transplantation: a case report. Yen CC; Chen PM; Chiou TJ; Hsieh RK Zhonghua Yi Xue Za Zhi (Taipei); 1997 Feb; 59(2):126-31. PubMed ID: 9175303 [TBL] [Abstract][Full Text] [Related]
9. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Ruutu T; Niederwieser D; Gratwohl A; Apperley JF Bone Marrow Transplant; 1997 Apr; 19(8):759-64. PubMed ID: 9134165 [TBL] [Abstract][Full Text] [Related]
10. Thalidomide responsive chronic pulmonary GVHD. Forsyth CJ; Cremer PD; Torzillo P; Iland HJ; Young GA Bone Marrow Transplant; 1996 Feb; 17(2):291-3. PubMed ID: 8640183 [TBL] [Abstract][Full Text] [Related]
11. Anti-host cytotoxic T cells of bone marrow transplant recipients with or without graft-versus-host disease are equally sensitive to cyclosporin A. Liem LM; van Noort JT; Goulmy E Bone Marrow Transplant; 1996 Jul; 18(1):73-8. PubMed ID: 8831998 [TBL] [Abstract][Full Text] [Related]
12. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis. Kalhs P; Brugger S; Schwarzinger I; Greinix HT; Keil F; Kyrle PA; Knöbl P; Schneider B; Höcker P; Linkesch W Transplantation; 1995 Nov; 60(9):949-57. PubMed ID: 7491699 [TBL] [Abstract][Full Text] [Related]
13. [Digestive manifestations of graft-versus-host disease (GVHD) in bone marrow transplantation, organ transplantation and transfusion]. Li V; Molina L; Michallet M; Hostein J Gastroenterol Clin Biol; 1992; 16(1):29-36. PubMed ID: 1537479 [No Abstract] [Full Text] [Related]
14. The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. Markus PM; Cai X; Selvaggi G; Cooper M; Harnaha J; Fung JJ; Starzl TE Transplant Proc; 1991 Dec; 23(6):3232-3. PubMed ID: 1721418 [No Abstract] [Full Text] [Related]
15. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937 [TBL] [Abstract][Full Text] [Related]
16. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation. Koehler MT; Howrie D; Mirro J; Neudorf S; Blatt J; Corey S; Wollman M; Kelly-Ekeroth V; Reyes J Bone Marrow Transplant; 1995 Jun; 15(6):895-9. PubMed ID: 7581088 [TBL] [Abstract][Full Text] [Related]
17. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation. Schwinghammer TL; Bloom EJ Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255 [TBL] [Abstract][Full Text] [Related]
19. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846 [TBL] [Abstract][Full Text] [Related]
20. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]